PR Newswire Clinical TrialsOriginal article
Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
Phase 3RelcobatinibPositive
AI Analysis
Summary
Enliven Therapeutics announced FDA alignment on the Phase 3 ENABLE-2 trial design for relcobatinib in previously treated chronic myeloid leukemia, with plans to initiate the trial before year-end 2026.
Clinical Trial Data
Phase
Phase 3
Outcome Details
FDA alignment on ENABLE-2 Phase 3 trial design
Importance:6/10
Sentiment:
0.60
Phase 3FDA alignmentCMLtrial designsmall molecule
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 6, 2026 8:05 PM